title: Effect of somatostatin in advanced gastric cancer after D2 radical gastrectomy.
abstract: OBJECTIVE
  To study the effect of somatostatin in patients with advanced gastric cancer who received D2 lymphadenectomy and vagina vasorum dissection.
  
  
  METHODS
  Using a prospective, single-blind, placebo-controlled design, patients with advanced gastric cancer were randomized into a study group (n = 61) and a control group (n = 59). Patients in the study group were given somatostatin for 5-7 d starting 6 h after the operation, and patients in the control group were given normal saline. Preoperative and nonoperative complications in the perioperative period, as well as different types of postoperative drainage in the two groups were compared.
  
  
  RESULTS
  There was no significant difference between the study group and the control group for preoperative clinicopathological indicators. We found no significant difference between the two groups for the overall incidence of complications, but a lower percentage of peritoneal effusion was observed in the treatment group (1.6% vs 10.2%, P < 0.05). There were no significant differences between the two groups in the incidence of postoperative pancreatic dysfunction and chylous fistula. However, there were significant differences in the amylase concentration in drainage fluid, volume and duration of drainage, volume and duration of chylous fistula and peritoneal drainage, and volume and duration of gastric tube drainage. The study group did not show any increase in mean hospitalization cost and the cost reduced when the postoperative complications occurred.
  
  
  CONCLUSIONS
  Postoperative somatostatin reduces volume and duration of surgical drainage and related complications. Somatostatin may improve safety of gastric cancer surgery, reducing postoperative complications and promoting recovery.
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Wu
authors.initials: W
authors.lastname: Song
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Jian-Hui
authors.initials: JH
authors.lastname: Chen
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Xin-Hua
authors.initials: XH
authors.lastname: Zhang
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Jian-Bo
authors.initials: JB
authors.lastname: Xu
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Yu-Long
authors.initials: YL
authors.lastname: He
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Shi-Rong
authors.initials: SR
authors.lastname: Cai
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Fang-Hai
authors.initials: FH
authors.lastname: Han
authors.affiliation: Wu Song, Jian-Hui Chen, Xin-Hua Zhang, Jian-Bo Xu, Yu-Long He, Shi-Rong Cai, Fang-Hai Han, Chuang-Qi Chen, Gastric Cancer Center, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
authors.forename: Chuang-Qi
authors.initials: CQ
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002681:China; D004322:Drainage; D004334:Drug Administration Schedule; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D016037:Single-Blind Method; D013004:Somatostatin / Q000008:administration & dosage* / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013004:Somatostatin
keywords: Advanced gastric cancer; Complications; Somatostatin